Novartis.com | Contact Us | Help | Site Map | Stay Connected | Large Text Version Regular Text Version

Home
Media
Press Releases

Cancer Press Releases at Novartis Oncology

This content is intended for non-U.S. journalists. U.S. journalists, please visit the U.S. Media Room

Press Releases

10-Dec-2009

Further analysis of BIG 1-98 data supports survival advantage for Novartis drug Femara^® over tamoxifen in breast cancer patients

Select a year: 2010 | 2009 | 2008 | 2007 | 2006

Subscribe to RSS

How to subscribe to RSS feeds

09-Dec-2007

New data show Glivec® halts progression to advanced stages of life-threatening form of leukemia in sixth year of treatment

28-Nov-2007

Tasigna® gains European approval for patients with a life-threatening form of leukemia who are resistant or intolerant to existing therapies

29-Oct-2007

Tasigna® receives US approval providing new hope to chronic myeloid leukemia patients with resistance or intolerance to existing therapies

21-Sep-2007

Tasigna® recommended for European approval to treat rare form of leukemia no longer responding to Glivec®

19-Apr-2007

Novartis expands late-stage oncology pipeline with AS1404, a novel agent shown to break down blood vessels that support tumor growth

17-Apr-2007

Reclast® receives US approval as a highly effective treatment for patients with Paget's disease of the bone

15-Feb-2007

Novartis seeking clarity in Indian patent laws, a critical incentive for long-term R&D investments into better medicines for patients

7 Total results

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on Novartis' website for historical purposes only. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.

SEARCH OUR WEBSITES

ABOUT NOVARTIS ONCOLOGY

Learn More About Novartis Oncology

We deliver a broad range of innovative therapies, cancer resources and oncology drugs to improve and extend the lives of cancer patients.

Learn more about Novartis Oncology

Use of this website is governed by our Terms of Use and Privacy Policy. © Novartis AG

Disclaimer: This site is intended to provide information to audiences outside the United States. Please note that not all products listed within this site may be available in all countries. Also, prescribing information and indications for products may differ from country to country, so please consult your local Novartis company for local prescribing and any other information you may be interested in.